At the annual Frost & Sullivan Excellence in Medical Technology Awards attended by us on Wednesday, Nephros, out of Dublin, Ireland, won the Medical Device Patient Care Company of the Year Award. The firm has developed hemodiafiltration technology for people with end-stage renal disease (ESRD). The company’s OLpur™ H2H™ device works in conjunction with an existing dialysis machine to provide an additional layer of filtration.
Here’s how the system works from the product page:
The OLpur H2H is a small, user-friendly module that resides on a “holder” next to a standard dialysis machine. It operates completely independently from the clinic’s dialysis machine, incorporating all controls and monitors necessary to provide safe and effective hemodiafiltration therapy. It offers on-line ultrapure substitution fluid, and incorporates cleaning technology and redundant safety features designed to provide a safe and effective treatment.
The OLpur H2H incorporates a reusable substitution fluid filter with built-in redundancy, providing injectable-grade fluid from dialysate; the fluid exceeds the requirements of USP and EP Sterile Water for Injection.
The OLpur H2H also incorporates on-board heat disinfection to provide nightly disinfection of the system and substitution fluid filter.
The OLpur H2H offers a mode- and context-sensitive user interface (UI) that presents the user with a logical sequence of selections. The system provides appropriate instructions and choices in real-time, offering a
simplified panel for informational scrolling and choice selection. The OLpur H2H also maintains an awareness of its “state” at all times, and guides the user accordingly, thus effectively locking out incorrect selections and actions.